IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.
Published April 20, 2022 · Recall initiated: March 29, 2022
Summary
FDA records drug Class I recall D-0765-2022, published April 20, 2022 and initiated March 29, 2022. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 1565 vials; Lot: Lot #: 31329657B, Exp. Date 08/2023. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Particulate Matter: Product was found to contain silica and iron oxide
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Teva Pharmaceuticals USA Inc
- Distributor
- Nationwide within the United States
- Lot
- Lot #: 31329657B, Exp. Date 08/2023
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDASunitinib Malate Capsules, 12.5 mg, 28-count bottles, Rx only, Manufactured By: Teva Pharmaceuticals USA,July 19, 2023
- FDAFentanyl Buccal Tablets CII, 600mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only,May 31, 2023
- FDAFentanyl Buccal Tablets CII, 400mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only,May 31, 2023
- FDAFentanyl Buccal Tablets CII, 200mcg, packaged in cartons of 28 Buccal Tablets (4 tablets x 7 cards), Rx only,May 31, 2023
- FDACyanocobalamin Injection, USP, 1,000 mcg per mL, For IM or SC Use Only, 1 mL Vial, Rx Only, Manufactured inApril 20, 2022
- FDAFirst SIGN SARS-CoV-2 Antigen TestApril 13, 2022
Questions about this recall
Was IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11. recalled?
Yes. FDA published recall D-0765-2022 on April 20, 2022. Reported hazard: Presence of Particulate Matter: Product was found to contain silica and iron oxide
What should I do if I have this product?
Voluntary: Firm initiated · Letter